tg4001
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 11, 2017 (NCT03260023)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03260023 | Phase 1/Phase 2 (Phase 2) | Sep 11, 2017 | Merck KGaA, Merck Serono, Pfizer, Transgene |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 1 | 0 | 1 | 2017 |
| Merck Serono | For profit | 1 | 0 | 1 | 2017 |
| Pfizer | For profit | 1 | 0 | 1 | 2017 |
| Transgene | For profit | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1